» Articles » PMID: 11220737

Increased Expression of the Pro-inflammatory Enzyme Cyclooxygenase-2 in Amyotrophic Lateral Sclerosis

Overview
Journal Ann Neurol
Specialty Neurology
Date 2001 Feb 28
PMID 11220737
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in the copper/zinc superoxide dismutase (mSOD1) gene are associated with a familial form of amyotrophic lateral sclerosis (ALS), and their expression in transgenic mice produces an ALS-like syndrome. Recent observations suggest a role for inflammatory-related events in the progression and propagation of the neurodegenerative process in ALS. Consistent with this view, the present study demonstrates that, during the course of the disease, the expression of cyclooxygenase type 2 (Cox-2), a key enzyme in the synthesis of prostanoids, which are potent mediators of inflammation, is dramatically increased. In both early symptomatic and end-stage transgenic mSOD1 mice, neurons and, to a lesser extent, glial cells in the anterior horn of the spinal cord exhibit robust Cox-2 immunoreactivity. Cox-2 mRNA and protein levels and catalytic activity are also significantly increased in the spinal cord of the transgenic mSOD1 mice. The time course of the spinal cord Cox-2 upregulation parallels that of motor neuronal loss in transgenic mSOD1 mice. We also show that Cox-2 activity is dramatically increased in postmortem spinal cord samples from sporadic ALS patients. We speculate that Cox-2 upregulation, through its pivotal role in inflammation, is instrumental in the ALS neurodegenerative process and that Cox-2 inhibition may be a valuable therapeutic avenue for the treatment of ALS.

Citing Articles

Prostaglandins in the Inflamed Central Nervous System: Potential Therapeutic Targets.

Sheremeta C, Yarlagadda S, Smythe M, Noakes P Curr Drug Targets. 2024; 25(13):885-908.

PMID: 39177131 PMC: 11774313. DOI: 10.2174/0113894501323980240815113851.


LRRK2 Kinase Inhibition Attenuates Neuroinflammation and Cytotoxicity in Animal Models of Alzheimer's and Parkinson's Disease-Related Neuroinflammation.

Mutti V, Carini G, Filippini A, Castrezzati S, Giugno L, Gennarelli M Cells. 2023; 12(13).

PMID: 37443833 PMC: 10340668. DOI: 10.3390/cells12131799.


Update on the pathological roles of prostaglandin E in neurodegeneration in amyotrophic lateral sclerosis.

Nango H, Tsuruta K, Miyagishi H, Aono Y, Saigusa T, Kosuge Y Transl Neurodegener. 2023; 12(1):32.

PMID: 37337289 PMC: 10278279. DOI: 10.1186/s40035-023-00366-w.


In Silico Exploration of Metabolically Active Peptides as Potential Therapeutic Agents against Amyotrophic Lateral Sclerosis.

Fatoki T, Chukwuejim S, Udenigwe C, Aluko R Int J Mol Sci. 2023; 24(6).

PMID: 36982902 PMC: 10058213. DOI: 10.3390/ijms24065828.


Analysis of Sex-Specific Prostanoid Production Using a Mouse Model of Selective Cyclooxygenase-2 Inhibition.

Upmacis R, Becker W, Rattendi D, Bell R, Jordan K, Saniei S Biomark Insights. 2022; 17:11772719221142151.

PMID: 36533270 PMC: 9749041. DOI: 10.1177/11772719221142151.